What ISO 14117 Covers and Why It Exists

ISO 14117 is the international standard that specifies electromagnetic compatibility test methods and acceptance criteria specifically for active implantable medical devices — including cardiac pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronisation therapy systems. It exists because active implantable devices operate inside the human body in close proximity to conductive lead systems, creating electromagnetic coupling pathways that no general-purpose EMC standard adequately addresses.

The standard emerged from a recognised gap: general medical device EMC standards such as IEC 60601-1-2 were designed for external equipment and do not capture the specific exposure scenarios relevant to implanted systems. When an implanted pacemaker lead acts as an unintentional antenna, the induced voltages and currents at the device input can trigger inappropriate pacing inhibition, false sensing, or in extreme cases, device reset — outcomes with direct clinical consequences. ISO 14117 was therefore developed to define the exposure conditions, test configurations, and performance thresholds that reflect real-world electromagnetic environments encountered by patients in daily life and clinical settings.

The standard addresses both the device itself and its associated programmer or external communication system, recognising that telemetry links and inductive charging interfaces introduce additional electromagnetic interaction pathways. Engineers working on active implantable medical devices must treat ISO 14117 as a primary design constraint — not a post-development compliance exercise — because its requirements shape antenna geometry, shielding architecture, filter design, and firmware response to detected interference.

The Three Core EMC Test Categories Under ISO 14117

ISO 14117 organises electromagnetic compatibility validation into three distinct test categories — radiated immunity, conducted immunity, and electrostatic discharge — each targeting a different electromagnetic coupling mechanism and requiring separate test configurations and acceptance criteria.

Radiated Immunity

Radiated immunity testing exposes the implant system — device, leads, and programmer — to electromagnetic fields generated by external sources. The standard defines field strengths, frequency ranges, and modulation conditions that represent real-world interference sources encountered by patients, including consumer electronics, wireless communication systems, industrial equipment, and medical imaging infrastructure. The implant is positioned within a tissue-simulating phantom during exposure so that the coupling of the external field to the lead system reflects realistic in-body conditions rather than free-space exposure. Engineers must demonstrate that the device maintains its intended therapeutic function throughout the exposure and returns to normal operation when the field is removed.

Conducted Immunity

Conducted immunity testing addresses signals that are coupled directly onto the device’s leads, electrode connections, or programmer interface rather than arriving via radiated propagation. This category is particularly important for active implantable devices because implanted leads can extend tens of centimetres through the body, acting as efficient conductors for low-frequency interference. Test signals are injected at defined levels into the lead or connector interface, and the device’s response is monitored for inappropriate output changes. Telemetry links and inductive charging interfaces represent additional conducted pathways that must be characterised under this category.

Electrostatic Discharge

ESD testing evaluates the device’s resilience to the sudden discharge of static electricity — a hazard that can occur when a patient or clinician touches the programmer, the implant pocket, or any externally accessible surface. ISO 14117 specifies both contact discharge and air discharge methods applied to defined test points on the programmer housing and any externally accessible implant surfaces. The acceptance criterion requires that the device sustains no permanent damage and returns to its pre-discharge functional state.

“Implanted leads can extend tens of centimetres through the body, acting as efficient conductors for low-frequency interference — making conducted immunity testing a critical and device-specific validation challenge.”

Phantom Models and Test Setup Requirements

The tissue-simulating phantom is the defining feature of ISO 14117 radiated immunity testing and the element that most clearly distinguishes it from general EMC standards. A phantom is a container — typically a flat or torso-shaped vessel — filled with a saline solution or gel formulated to replicate the dielectric properties and conductivity of human tissue at the frequencies of interest.

The implant and its lead system are positioned within the phantom according to geometries specified in the standard, simulating the anatomical placement of a pacemaker in the pectoral region with leads routed through the venous system to the heart. This geometry is critical: the coupling of an external electromagnetic field to the lead system is strongly dependent on lead length, routing angle relative to the incident field polarisation, and the electrical properties of the surrounding medium. A test performed in free space — without the phantom — would systematically underestimate or mischaracterise the induced voltages at the device input.

Engineers must also account for the interaction between the phantom and the test antenna’s near field. At lower frequencies, the phantom’s saline fill can load the antenna and alter the field distribution in the test volume. Calibration of the field at the intended device location — with the phantom present but without the device — is therefore a prerequisite step, not an optional refinement. The standard specifies calibration procedures that account for this loading effect, ensuring that the device under test is exposed to the intended field strength rather than an approximation of it.

Defining Pass/Fail Criteria Against Clinical Risk

Pass/fail criteria under ISO 14117 are grounded in clinical outcomes rather than arbitrary signal thresholds. The standard defines acceptable device behaviour during and after electromagnetic exposure in terms of performance levels that correspond to clinically meaningful risk thresholds — a framework that requires engineers to understand both the device’s therapeutic function and the clinical consequences of its failure modes.

For a cardiac pacemaker, the critical failure modes are well defined: inappropriate inhibition of pacing output in a pacing-dependent patient, inappropriate delivery of a shock by an ICD, or reversion to an asynchronous pacing mode that could cause competitive pacing. ISO 14117’s performance level framework maps these failure modes to acceptance criteria, distinguishing between transient effects that resolve when the field is removed — which may be acceptable — and permanent changes to device configuration or output that are not. Engineers must characterise the device’s response across the full range of test conditions and demonstrate that no unacceptable performance level is reached.

The performance level assessment also requires engineers to consider the device’s programmed settings at the time of testing. A pacemaker operating in a unipolar sensing configuration presents a larger effective antenna aperture than the same device in bipolar mode, and will therefore be more susceptible to radiated fields. ISO 14117 addresses this by requiring testing in the worst-case programmed configuration — the one most likely to produce a clinically significant response — rather than the device’s default factory settings. Identifying that worst-case configuration requires systematic analysis of the device’s sensing architecture and an understanding of how different lead configurations alter the coupling geometry.

Post-exposure assessment is equally important. After each test sequence, engineers must verify that the device has returned to its pre-test functional state — correct sensing thresholds, pacing output amplitude and pulse width, and programmed mode. Any persistent deviation constitutes a failure regardless of whether the device appeared to function during the exposure period. This requirement drives the need for comprehensive pre- and post-test characterisation protocols that go beyond simple functional checks.

Regulatory Recognition and Submission Strategy

ISO 14117 is recognised by the four major regulatory jurisdictions for active implantable devices — the European Union, the United States, Canada, and Australia — making it the most widely accepted single standard for AIMD electromagnetic compatibility compliance evidence.

In the European Union, ISO 14117 is cited under EU Medical Device Regulation 2017/745 (MDR) as a harmonised standard. Conformance with a harmonised standard creates a presumption of conformity with the corresponding essential requirements of the MDR — in this case, the electromagnetic compatibility requirements of Annex I. Manufacturers who demonstrate ISO 14117 conformance can reference it in their technical documentation and Declaration of Conformity, significantly streamlining the notified body review of EMC evidence.

In the United States, the FDA recognises ISO 14117 as a consensus standard under its standards recognition programme. Manufacturers submitting a 510(k) or PMA application can reference ISO 14117 test reports as part of their electromagnetic compatibility evidence, with the FDA’s recognition of the standard providing a documented basis for the chosen test approach. The FDA’s guidance on the use of consensus standards notes that conformance with a recognised standard satisfies the corresponding regulatory requirement without requiring the agency to re-evaluate the underlying technical rationale.

For global submissions, engineers and regulatory affairs teams should note that ISO 14117 conformance does not automatically satisfy all jurisdictional requirements. Some markets require supplementary testing to national standards or additional documentation of the test laboratory’s accreditation status. According to ISO, the standard undergoes periodic revision to reflect changes in the electromagnetic environment — including the introduction of new wireless communication technologies — and manufacturers must monitor the current edition to ensure their test programmes remain current. The transition from one edition to another can require additional testing if the new edition introduces more stringent field strengths or expanded frequency ranges.

Regulatory strategy around ISO 14117 also intersects with post-market surveillance obligations. Manufacturers are expected to monitor field reports of electromagnetic interference incidents and assess whether those incidents fall within the tested and accepted performance envelope. If a new interference source — such as a new wireless standard operating in a frequency range not covered by the current ISO 14117 edition — is identified as a potential hazard, manufacturers may need to conduct supplementary testing and update their risk management documentation accordingly, in line with requirements from bodies such as WHO and national competent authorities.